Sanofi Quarterly Results
Sanofi quarterly results. In Mar 2025, Sanofi (SANOFI) reported revenue ₹539 Cr and net profit ₹120 Cr — revenue -6.9% YoY. Review SANOFI earnings multiple to evaluate earnings-based valuation against sector peers.
SANOFI Quarterly Results — Revenue, Profit & EPS Highlights
Sanofi latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit SANOFI share price screener.
- Revenue of ₹539 Cr in Mar 2025 (+2.5% vs Sept 2024, -6.9% vs Mar 2024)
- Net Profit of ₹120 Cr in Mar 2025 (+46.3% vs Sept 2024, -12.4% vs Mar 2024)
- EBITDA of ₹175 Cr in Mar 2025 (+43.4% vs Sept 2024)
- Operating Margin of 32.0% in Mar 2025 (+9.0pp vs Sept 2024)
- Earnings Per Share of ₹51.89 in Mar 2025 (+45.4% vs Sept 2024)
Sanofi Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SANOFI quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 539 | 526 | 579 | 503 | 529 | 2.5% | -6.9% |
| Net Profit (₹ Cr) | 120 | 82 | 137 | 103 | 91 | - | - |
| EBITDA (₹ Cr) | 175 | 122 | 179 | 137 | 132 | - | - |
| EPS (₹) | 51.89 | 35.69 | 59.31 | 44.81 | 39.64 | - | - |
| Operating Margin (%) | 32.0% | 23.0% | 22.0% | 21.0% | 23.0% | - | - |
SANOFI Share Price Trend — 1-Year Movement Across Quarterly Results
Sanofi 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check SANOFI company valuation to track the company's total market size over time.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SANOFI vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sanofi latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹253,522.49 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Cipla
Mar 2026 |
₹108,576.18 Cr | 1335.5 | 6,612 | 543 | -9.3% | - | 8.2% | 194.4 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores